Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2012
NEW YORK, Sept. 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Partnerships, Licensing, Investments and M&A Deals andTrends in Pharmaceuticals - Q2 2012
http://www.reportlinker.com/p0961803/Partnerships-Licensing-Investments-and-MA-Deals-andTrends-in-Pharmaceuticals---Q2-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking
Partnerships, Licensing, Investments and M&A Deals andTrends in Pharmaceuticals - Q2 2012
Summary
GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2012" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q2 2012. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and primary and secondary research.
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Industry Insights 8
3 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2012 9
3.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2012 9
3.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, Q2 2012 11
3.3 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2012 12
3.3.1 Nestle to Acquire Pfizer Nutrition from Pfizer for $11.85 Billion 12
3.3.2 Walgreen to Acquire 45% Stake in Alliance Boots from KKR And AXA Private Equity for $6.7 Billion 12
3.3.3 Watson Pharma to Acquire Swiss Drug Maker Actavis Group for Up to $5.92 Billion 13
3.3.4 Bristol-Myers Squib Commences Tender Offer to Acquire Amylin Pharma for $5.3 Billion 13
3.3.5 DaVita Receives Antitrust Approval to Acquire HealthCare Partners, Doctor Network Operator, for Up to $4.7 Billion 13
4 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 14
4.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2012 14
4.1.1 Top M&A Deals in Q2 2012 15
4.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2011 - Q2 2012 16
4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2012 17
4.2.1 Top Initial Public Offerings in Q2 2012 18
4.2.2 Top Secondary Offerings in Q2 2012 18
4.2.3 Top PIPE Deals in Q2 2012 18
4.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2011-Q2 2012 19
4.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2011 - Q2 2012 20
4.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2012 21
4.3.1 Top Venture Financing Deals in Q2 2012 22
4.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2012 23
4.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2011 - Q2 2012 24
4.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 25
4.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 26
4.3.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2012 27
4.3.7 Top Private Equity Deals in Q2 2012 28
4.3.8 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2011 - Q2 2012 29
5 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2012 30
5.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2012 30
5.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2011 - Q2 2012 31
5.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 32
5.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2012 33
5.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2012 33
5.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2012 34
5.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 - Q2 2012 35
5.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 36
5.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 - Q2 2012 37
6 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2012 38
6.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2012 38
6.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 - Q2 2012 39
6.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2012 40
6.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2012 40
6.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2012 41
6.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2011 - Q2 2012 42
6.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2011 - Q2 2012 43
6.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2011 - Q2 2012 44
6.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2011 - Q2 2012 45
7 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 46
7.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q2 2011 - Q2 2012 46
7.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q2 2011 - Q2 2012 47
7.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2011 - Q2 2012 48
7.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2011 - Q2 2012 49
7.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q2 2011 - Q2 2012 50
7.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q2 2011 - Q2 2012 51
7.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2011 - Q2 2012 52
8 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 53
8.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2012 53
8.1.1 Oncology - Deals of the Quarter 54
8.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2012 55
8.2.1 Central Nervous System - Deals of the Quarter 56
8.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2012 57
8.3.1 Infectious Disease - Deals of the Quarter 58
8.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2012 59
8.4.1 Immunology - Deals of the Quarter 60
8.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2012 61
8.5.1 Metabolic Disorders - Deals of the Quarter 62
8.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2012 63
8.6.1 Cardiovascular - Deals of the Quarter 64
8.7 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2012 65
8.7.1 Dermatology - Deals of the Quarter 66
8.8 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2012 67
8.8.1 Gastrointestinal - Deals of the Quarter 68
8.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2012 69
8.9.1 Respiratory - Deals of the Quarter 70
8.10 Pharmaceuticals & Healthcare, Global, Musculoskeletal Deals, Q2 2012 71
8.10.1 Musculoskeletal - Deals of the Quarter 72
9 Deal Summary by Geography 73
9.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2012 73
9.1.1 North America - Deals of the Quarter 74
9.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2012 76
9.2.1 Europe - Deals of the Quarter 77
9.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2012 79
9.3.1 Asia-Pacific - Deals of the Quarter 80
9.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2012 82
9.4.1 Rest of the World - Deals of the Quarter 83
10 Pharmaceuticals & Healthcare, Global, Top Advisors 84
10.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 84
10.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 85
11 Appendix 86
12 Further Information 91
12.1 Methodology 91
12.2 About GlobalData 91
12.3 Contact Us 92
12.4 Disclosure information 92
12.5 Disclaimer 92
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q2 2011 - Q2 2012 10
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2012 11
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2012 12
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 14
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q2 2012 15
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q2 2011 - Q2 2012 16
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2011 - Q2 2012 17
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q2 2012 18
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2012 18
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2012 18
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2011-Q2 2012 19
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2011 - Q2 2012 20
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 21
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2012 22
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2012 23
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2011 - Q2 2012 24
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2011 - Q2 2012 25
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2011 - Q2 2012 26
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 27
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q2 2012 28
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2011 - Q2 2012 29
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 30
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 31
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 - Q2 2012 32
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 33
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2012 33
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2012 34
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2011 - Q2 2012 35
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2011 - Q2 2012 36
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2011 - Q2 2012 37
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 38
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 - Q2 2012 39
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2012 40
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2012 40
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2012 41
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 42
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2011 - Q2 2012 43
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2011 - Q2 2012 44
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2011 - Q2 2012 45
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2011 - Q2 2012 46
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2011 - Q2 2012 47
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2011 - Q2 2012 48
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q2 2011 - Q2 2012 49
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2009 - Q2 2012 50
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q2 2011 - Q2 2012 51
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2011 - Q2 2012 52
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 54
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 56
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 57
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 59
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 61
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 63
Table 53: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 65
Table 54: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 67
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 69
Table 56: Pharmaceuticals & Healthcare, Global, Musculoskeletal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 71
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 74
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 77
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 80
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 83
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2011 - Q2 2012 84
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2011 - Q2 2012 85
Table 63: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q2 2011-Q2 2012 86
List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q2 2011 - Q2 2012 9
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%), Q2 2012 11
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q2 2011 - Q2 2012 14
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q2 2011 - Q2 2012 16
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 17
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q2 2011 - Q2 2012 20
Figure 7: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 21
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Values (%), Q2 2012 23
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2011 - Q2 2012 24
Figure 10: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2011 - Q2 2012 25
Figure 11: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 27
Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2011 - Q2 2012 29
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 30
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 31
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2011 - Q2 2012 32
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2011 - Q2 2012 35
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2011 - Q2 2012 36
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2011 - Q2 2012 37
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 38
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2011 - Q2 2012 39
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 42
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 - Q2 2012 43
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 44
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 - Q2 2012 45
Figure 25: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2011 - Q2 2012 46
Figure 26: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2011 - Q2 2012 47
Figure 27: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2011 - Q2 2012 48
Figure 28: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2011 - Q2 2012 49
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q2 2011 - Q2 2012 50
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q2 2011 - Q2 2012 51
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2011 - Q2 2012 52
Figure 32: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 53
Figure 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 55
Figure 34: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 57
Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 59
Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 61
Figure 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 63
Figure 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 65
Figure 39: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 67
Figure 40: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 69
Figure 41: Pharmaceuticals & Healthcare, Global, Musculoskeletal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 71
Figure 42: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 73
Figure 43: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 76
Figure 44: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 79
Figure 45: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q2 2011 - Q2 2012 82
Figure 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2011 - Q2 2012 84
Figure 47: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2011 - Q2 2012 85
To order this report:
Investment_Banking Industry: Partnerships, Licensing, Investments and M&A Deals andTrends in Pharmaceuticals - Q2 2012
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article